Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events

Clinical success of immune-checkpoint blockade (ICB) cancer immunotherapy is compromised by increased risk of immune-related adverse events (irAEs). However, mechanistic action(s) of immune responses underlying development of irAE remain not fully explored. Here, we found that in tumor-bearing aged,...

Full description

Bibliographic Details

Published in:	Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 29; p. e2205378119
Main Authors:	Tsukamoto, Hirotake, Komohara, Yoshihiro, Tomita, Yusuke, Miura, Yuji, Motoshima, Takanobu, Imamura, Kosuke, Kimura, Toshiki, Ikeda, Tokunori, Fujiwara, Yukio, Yano, Hiromu, Kamba, Tomomi, Sakagami, Takuro, Oshiumi, Hiroyuki
Format:	Journal Article
Language:	English
Published:	United States 19.07.2022
Subjects:	Aging - immunology Animals CD4-Positive T-Lymphocytes - immunology Chemokine CXCL13 - immunology Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immune System Diseases - etiology Immunotherapy - adverse effects Lymphocyte Activation Mice Neoplasms - therapy Programmed Cell Death 1 Receptor - antagonists & inhibitors
ISSN:	1091-6490, 1091-6490
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!